Drew Palermo
Physician Assistant · Perrysburg, OHNPI 1598306334
Payments from drug & device makers
Across 284 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$986
- AbbVie$570
- Lilly USA, LLC$342
- Otsuka America Pharmaceutical, Inc.$257
- Pfizer$243
- Boehringer Ingelheim$213
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,47798%
- Education$782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 70 | $986 |
| AbbVie | 42 | $570 |
| Lilly USA, LLC | 25 | $342 |
| Otsuka America Pharmaceutical, Inc. | 16 | $257 |
| Pfizer | 15 | $243 |
| Boehringer Ingelheim | 14 | $213 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $196 |
| Exact Sciences | 9 | $182 |
| AstraZeneca | 4 | $165 |
| Boston Scientific | 2 | $160 |
| Amarin Pharma, Inc. | 10 | $155 |
| Novartis | 7 | $107 |
| Dexcom, Inc. | 6 | $100 |
| Daiichi Sankyo Inc. | 5 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $79 |
| Astellas Pharma US Inc | 1 | $66 |
| Corcept Therapeutics | 3 | $64 |
| Kowa Pharmaceuticals America, Inc. | 3 | $58 |
| Merck | 4 | $57 |
| Biohaven Pharmaceuticals, Inc. | 3 | $51 |
| Abbott | 3 | $49 |
| Bayer | 3 | $47 |
| Amgen | 3 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| GSK | 2 | $30 |
| Genentech USA, Inc. | 2 | $29 |
| Phadia US Inc. | 2 | $29 |
| Endogastric Solutions, Inc | 2 | $22 |
| Vivus LLC | 1 | $21 |
| GRT US Holding, Inc. | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $18 |
| Corium, LLC | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$144
- Saxenda$115
How this compares
$4,555 in reported general payments places this provider in the 90th percentile of 4,098 physician assistant providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $38,567 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $30,819 |
| EliquisApixaban | 45 | $29,320 |
| JardianceEmpagliflozin | 22 | $24,646 |
| MounjaroTirzepatide | 17 | $24,199 |
| JanuviaSitagliptin Phosphate | 29 | $24,161 |
| FarxigaDapagliflozin Propanediol | 20 | $16,599 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $4,199 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,093 |
| Atorvastatin Calcium | 277 | $2,184 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,495 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,082 |
| Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm | 12 | $1,044 |
| Levothyroxine Sodium | 94 | $980 |
| Gabapentin | 81 | $956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $986 | $38,56735 claims |
| GSKTrelegy Ellipta | $30 | $30,81943 claims |
| PfizerEliquis | $243 | $29,32045 claims |
| Boehringer IngelheimJardiance | $213 | $24,64622 claims |
| Lilly USA, LLCMounjaro | $342 | $24,19917 claims |
| MerckJanuvia | $57 | $24,16129 claims |
| AstraZenecaFarxiga, Symbicort | $165 | $20,69233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,098 physician assistant providers in Ohio.
Other physician assistant in Perrysburg
- Sherri WhitcombPerrysburg$13K
- Steven WurzelbacherCincinnati$309K
- Emily AnkromDayton$192K
- Amanda MaggartWorthington$164K
- Megan SevillaMayfield Heights$132K
- Erin StrculaBelpre$106K
- Natalie WalkupSylvania$105K
- Sarah LaubNew Albany$100K
- Jessica RhominskiCanal Winchester$78K
- Alan OdonnellCincinnati$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.